● SK chemicals SKYCellfluⓇ Quadrivalent receives award at ‘Medical Korea Awards 2016.’

- SKYCellflu®--Vaccine category’s only prize winner! Previously received Osong New Drug Award and the Highest Brand Award.
- SKYCellflu® vaccine’s efficacy recognized in the first year on the market∙∙∙ “SK chemicals will continue contributing to the development of the vaccine industry.”



The world’s first quadrivalent cell-cultured influenza vaccine, ‘SKYCellfluⓇ Quadrivalent,’ firmly established itself in the market in the first year after its launch, and became the most recognized brand in the vaccine category.

SK chemicals announced that it was the only company that received an award in the vaccine category at ‘Medical Korea Awards 2016’ held in the COEX Grand Ballroom in Samseong-dong, Seoul on November 24.

The Medical Korea Awards is an event, sponsored by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety, which selects and awards outstanding pharmaceutical companies, medical device manufacturers and hospitals that played a leading role in the advancement of the pharmaceutical industry this past year.

SK chemicals was the first in the world to develop and launch the ‘quadrivalent’ and ‘cell-cultured’ influenza vaccine ‘SKYCellfluⓇ Quadrivalent,’ and raised the technological level of the domestic pharmaceutical industry. In recognition of these accomplishments, SK chemicals became the only company to receive the Medical Korea Award in the vaccine category.

SKYCellfluⓇ Quadrivalent is a next-generation vaccine that can prevent four influenza viruses with a single injection. It offers protection against two type A influenza viruses (H1N1 and H3N2) and two type B viruses (Yamagata and Victoria).

Also, since SK chemicals adopted the cell-cultured method, i.e. producing vaccines in the state-of-the-art sterile incubator for culture without using fertile eggs, no preservative or antibiotics were used in the production process, and the production period was more than halved to 2~3 months.

Prof. Lee Jae-gap, Department of Infectious Diseases at Hallym University Kangnam Sacred Heart Hospital, who led the clinical study of SKYCellfluⓇ Quadrivalent, said, “The immunogenicity of SKYCellfluⓇ Quadrivalent was proven in all age groups above the age of 3 through a clinical study of 1,503 adults and 454 children.”

Also, Prof. Kim Yun-kyung, Department of Pediatrics, Korea University Ansan Hospital, said about the safety of the product, “No Serious Adverse Drug Reaction (SADR) was reported.”

SK chemicals obtained permission for the use of SKYCellfluⓇ Quadrivalent in adults last December, and expanded the coverage of vaccination to include children and juveniles aged between 3 and 18 last June. It is the only quadrivalent influenza vaccine produced in Korea that can be used to vaccinate people of all ages above the age of three.

“We have been concentrating our R&D competency on development of vaccines, and accumulating differentiated technology since 2008,” said Kim Gyeong-geun, head of the Vaccine Marketing Headquarters at SK chemicals. “We will continue contributing to the development of the domestic vaccine industry by introducing a greater variety of vaccines in the future.”

SKYCellfluⓇ Quadrivalent received the Minister of Food & Drug Safety award at the ‘K-Health Leaders Forum Osong New Drug Awards,’ sponsored by the Korea Biotechnology Industry Organization, last September, and an award at ‘Korea Highest Brand 2016’ last October. The Korea Highest Brand awards are given to the representative brands of Korea that created the best values in the past year in each category.



[Photo]
Kim Gyeong-geun, head of Vaccine Marketing Headquarters at SK chemicals (right) is receiving the grand prize in the vaccine category for the world’s first quadrivalent cell-cultured influenza vaccine `SKYCellfluⓇ Quadrivalent` at `Medical Korea Awards 2016,` which was held on November 24.